Pegylated Interferon alpha 2-b

Medical Advocates
Pegylated Interferon Alfa-2b (PEG-INTRON)

HIV/HCV Conference Citations

18th CROI
17th CROI
XVII International AIDS Conference
13th CROI
XV International AIDS Conference
3rd IAS Conference
11th CROI

Peg Inf Alfa-2b HIV/HCV Main Page Main New/Newsworthy Home Page

Last Update: January 26, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

18th CROI

POSTER
PegIFN-a-2b + Weight-based RBV for 48 vs 72 Weeks in HIV/HCV Co-infected Patients: A Randomized Trial
M-L Vachon S Factor, R Sterling, et al
PDF Poster Abstract

17th CROI

Sustained Virologic Response (SVR) in HIV-HCV Co-infected Patients with HCV Genotype 1(G1)
Infection who have a Rapid Virological Response (RVR) at Week 4 of Treatment with Peginterferon
Alfa-2a (40KD) (PEG IFNa-2a, PEGASYSŽ) Plus Ribavirin (RBV, COPEGUSŽ): AIDS PEGASYS
Ribavirin International Co-infection Trial (APRICOT)
D Dieterich, F Duff, M Sulkowski, et al
Abstract
POSTER
Predictive Value of Early Virological Response to Treatment with Interferon-base Regimens
Plus Ribavirin in HIV Patients with Chronic Hepatitis C
M Laguno, M Larrousse, J Murillas, et al
PDF Poster Abstract

XVII Iinternational AIDS Conference

Efficacy of the treatment with peginterferon alfa-2a or peginterferon alfa-2b in co-infected patients treated at
the reference center for AIDS in Santos, SP, Brazil
M. Caseiro, S.O. Costa, M.H. Ventura, et al
Abstract

13th CROI

Sustained Virologic Response (SVR) in HIV-HCV Co-infected Patients with HCV Genotype 1(G1)
Infection who have a Rapid Virological Response (RVR) at Week 4 of Treatment with Peginterferon
Alfa-2a (40KD) (PEG IFNa-2a, PEGASYSŽ) Plus Ribavirin (RBV, COPEGUSŽ): AIDS PEGASYS
Ribavirin International Co-infection Trial (APRICOT)
D Dieterich, F Duff, M Sulkowski, et al
Abstract
POSTER
Predictive Value of Early Virological Response to Treatment with Interferon-base Regimens
Plus Ribavirin in HIV Patients with Chronic Hepatitis C
M Laguno, M Larrousse, J Murillas, et al
PDF Poster Abstract

3rd IAS Conference

Early hepatitis C viral kinetics prediction of SVR In HIV/Hcv co-infected patients
treated with pegylated interferon-alpha 2B (PEG-LFN) and ribavirin (RBV)
Neumann A., Wu L., McLaughlin M., Koratich C., et al
Abstract

XV Iinternational AIDS Conference

Interferon α 2b and ribavirin in the treatment of patients with chronic viral hepatitis C
coinfected with HIV preliminary report
E Mularska, M Beniowski, E Janczewska-Kazek, et al
Abstract
Final Results of ANRS HC02-RIBAVIC: A Randomized Controlled Trial of Pegylated-
Interferon-alfa-2b plus Ribavirin vs Interferon-alfa-2b plus Ribavirin for the Initial
Treatment of Chronic Hepatitis C in HIV Co-infected Patients
C Perronne, F Carrat, F Bani-Sadr, et al
Abstract

11th CROI

HCV Resistance to Peg-Interferon/Ribavirin Therapy Is Associated with Increased
Immune Activation in HIV/HCV Co-infected Patients
RA Lempicki, J Yang, G Dennis, et al
(Abstract

Peg Inf Alfa-2b HIV/HCV Main Page Main New/Newsworthy Home Page

Peginterferon Afa-2b HIV/HCV Indications